Study Summary
This trial seeks to determine whether taking low dose aspirin (LDA) can reduce long-term risk of cardiovascular disease in women who had preeclampsia during pregnancy.
- Prophylaxis of Preeclampsia
- Microvascular Function
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
2 Primary · 0 Secondary · Reporting Duration: at the study visit, an average of 4 hours
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
1 Treatment Group
assessment of microvascular function
1 of 1
Experimental Treatment
60 Total Participants · 1 Treatment Group
Primary Treatment: assessment of microvascular function · No Placebo Group · Phase < 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18 - 50 · Female Participants · 7 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Is it permissible to join this investigation if one is of an advanced age?
"The eligibility criteria for this research mandates that patients must be between 18 years and 50 years of age." - Anonymous Online Contributor
Is enrollment in this research endeavor still available?
"The current status of this medical trial, which was initially listed on March 1st 2023, is actively recruiting. As per the latest update from April 24th 2023, it can be found on clinicaltrials.gov." - Anonymous Online Contributor
How many participants is this study enrolling at present?
"Affirmative. According to the information located on clinicaltrials.gov, this study has been recruiting participants since its initial post date of March 1st 2023 and is currently seeking 60 people from one site." - Anonymous Online Contributor
Would I meet the criteria to take part in this investigation?
"This clinical trial is enrolling sixty persons aged 18 to 50 with a prior history of preeclampsia. In addition, individuals must meet the following criteria: being eighteen years or older; having had a normal gestation and abstaining from taking low-dose aspirin (LDA) during pregnancy; experiencing skin diseases; using tobacco products; suffering from hepatic or metabolic disorders such as chronic kidney disease (CKD), characterized by an eGFR lower than 60 mL/min/1.73m2s; and currently engaging in daily intake of aspirin within 12 weeks up to five years after delivering their baby." - Anonymous Online Contributor